There are many determinants of clot stability, however, in the context of anticoagulant drugs in general and FXI inhibitors particularly, as well as years of experience with mitigating bleeding risk and managing bleeding among persons with hemophilia C attenuating endogenous fibrinolysis and allowing fibrin generated by thrombin’s activation of fibrinogen are the primary goals (see sections on recombinant factor VII, concizumab, and antifibrinolytic agents below). Here, F7 is linked to congenital factor XI deficiency.